Who are acamprosate (Campral)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo-matching Rapastinel, Nerinetide (NA-1), NRX-101 Oral Capsule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acamprosate-campral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

acamprosate (Campral) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

acamprosate (Campral) (acamprosate (Campral)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor modulator. Area: Psychiatry / Addiction Medicine.

marketed NMDA receptor modulator NMDA receptor (glutamate); GABA system Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

acamprosate (Campral) (acamprosate (Campral)) — University of North Carolina, Chapel Hill. Acamprosate modulates glutamate and GABA neurotransmission to restore neurochemical balance disrupted by chronic alcohol use.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
acamprosate (Campral) TARGET	acamprosate (Campral)	University of North Carolina, Chapel Hill	marketed	NMDA receptor modulator	NMDA receptor (glutamate); GABA system
Placebo-matching Rapastinel	Placebo-matching Rapastinel	Naurex, Inc, an affiliate of Allergan plc	phase 3	NMDA receptor modulator	NMDA receptor (N-methyl-D-aspartate receptor)
Nerinetide (NA-1)	Nerinetide (NA-1)	NoNO Inc.	phase 3	NMDA receptor modulator / Neuroprotective peptide	PSD-95 (postsynaptic density protein 95)
NRX-101 Oral Capsule	NRX-101 Oral Capsule	NeuroRx, Inc.	phase 3	Fixed-dose combination (NMDA receptor modulator + atypical antipsychotic)	NMDA receptor (d-cycloserine component); dopamine D2 receptor and serotonin 5-HT7 receptor (lurasidone component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor modulator class)

Naurex, Inc, an affiliate of Allergan plc · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). acamprosate (Campral) — Competitive Intelligence Brief. https://druglandscape.com/ci/acamprosate-campral. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing